HANK MORGAN / SCIENCE PHOTO LIBRARY HANK MORGAN / SCIENCE PHOTO LIBRARY
Preparation of patient packages of VaxSyn, an experimental AIDS vaccine. Each pack contains the appropriate number of vaccine doses to treat a single patient for one year. VaxSyn is based on a genetically-engineered, recombinant form of the HIV protein gp160, which is a precursor to one of the outer surface proteins of the AIDS virus. VaxSyn contains no attenuated infectious parts of HIV & therefore carries no risk of transmitting AIDS. The vaccine is being developed by MicroGeneSys and is undergoing trials as a treatment of HIV-positive patients & as a potential vaccine against HIV infection.
Model release not available. Property release not required.